Pfizer Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert Bourla
- Full Time Employees
- 81,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 66 Hudson Boulevard East New York City NY United States of America 10001-2192
- IPO Date
- Jun 1, 1972
- CIK
- 0000078003
- Website
- pfizer.com
- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait
‘It Kills Me to Say That': Cramer Won't Recommend Pfizer, Even With Its 7% Dividend
3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
Opinion: Pfizer's Dividend Is Riskier Than You Might Think
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
2 Dirt Cheap Healthcare Stocks to Buy in July
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low
Meet the 4 S&P 500 Dividend Stocks That Yield at Least 6%. Here's My Strongest Buy of the Bunch in July.
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
Buy In July: 8 IDEAL 'Safer' S&P 500 DiviDogs
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?